Each year, cigarette smoking costs an estimated 418,000 American lives. Smoking cessation reduces this work, but is extremely difficult because smoking is maintained by factors such as nicotine withdrawal, tobacco's direct effects, and smoking-related stimuli that can control smoker's behavior. Current cessation methods address these factors. Nicotine replacement treatment suppresses withdrawal and/or blunts the effects of cigarettes. Behavioral treatments reduce the influence of smoking-related stimuli. Nonetheless, about 70% of smokers who try to quit, fail. Improving smoking subgroups, such as men and women. Treatment studies demonstrate that quitting is more difficult for women. There is no definitive explanation for this sex difference, but it may involve a differential response to nicotine replacement treatment and/or smoking- related stimuli. For women, nicotine replacement may be less effective at suppressing withdrawal symptoms (Hypothesis 1) or at blunting the effects of cigarettes smoked during a quit attempt (Hypothesis 2). Women may also be more sensitive to smoking-related stimuli, such as the taste, sight, and smell of cigarette smoke (Hypothesis 3). These hypotheses can be examined efficiently in the clinical laboratory. Strengths of this setting include control over extraneous variables, repeated measure designs that yield nicotine dose effect curves, and validated tools for measuring puff topography, tobacco withdrawal, and the direct effects of nicotine and/or cigarettes. Three such studies are proposed. In each study, 45 men and 45 women non-treatment seeking smokers will participate in 4 double blind, randomly ordered, 6.5-hour sessions. Objectively verified cigarette abstinence will be required before each session. Studies 1 and 2 will compare, in men and women, the nicotine dose response functions for suppression for tobacco withdrawal and for blunting the effects of cigarettes. Study 3 will compare, in men and women, the effects of smoking-related stimuli (denicotinized cigarettes). Thus hypotheses 1, 2, and 3 will be addressed in separate studies in this 5-year project. The project will help to elucidate the mechanism underlying oft-reported sex differences in smoking cessation and may help tailor combined pharmacological and behavioral treatments that maximize the likelihood of cessation for men and women smokers. Given the overwhelming costs of cigarette smoking and the dramatic reduction in those costs when smokers quit smoking, improving the treatment options for all American smokers is essential.

Agency
National Institute of Health (NIH)
Institute
National Institute on Drug Abuse (NIDA)
Type
Specialized Center (P50)
Project #
5P50DA005274-15
Application #
6630896
Study Section
Special Emphasis Panel (ZDA1)
Project Start
2002-07-01
Project End
2003-06-30
Budget Start
Budget End
Support Year
15
Fiscal Year
2002
Total Cost
Indirect Cost
Name
Virginia Commonwealth University
Department
Type
DUNS #
City
Richmond
State
VA
Country
United States
Zip Code
23298
Bagdas, Deniz; Alkhlaif, Yasmin; Jackson, Asti et al. (2018) New insights on the effects of varenicline on nicotine reward, withdrawal and hyperalgesia in mice. Neuropharmacology 138:72-79
Jackson, Kia J; Muldoon, Pretal P; Walters, Carrie et al. (2016) Neuronal calcium/calmodulin-dependent protein kinase II mediates nicotine reward in the conditioned place preference test in mice. Behav Pharmacol 27:50-6
Nass, Sara R; Long, Jonathan Z; Schlosburg, Joel E et al. (2015) Endocannabinoid Catabolic Enzymes Play Differential Roles in Thermal Homeostasis in Response to Environmental or Immune Challenge. J Neuroimmune Pharmacol 10:364-70
Muldoon, P P; Chen, J; Harenza, J L et al. (2015) Inhibition of monoacylglycerol lipase reduces nicotine withdrawal. Br J Pharmacol 172:869-82
Poklis, Justin L; Devers, Kelly G; Arbefeville, Elise F et al. (2014) Postmortem detection of 25I-NBOMe [2-(4-iodo-2,5-dimethoxyphenyl)-N-[(2-methoxyphenyl)methyl]ethanamine] in fluids and tissues determined by high performance liquid chromatography with tandem mass spectrometry from a traumatic death. Forensic Sci Int 234:e14-20
Poklis, Justin L; Nanco, Carol R; Troendle, Michelle M et al. (2014) Determination of 4-bromo-2,5-dimethoxy-N-[(2-methoxyphenyl)methyl]-benzeneethanamine (25B-NBOMe) in serum and urine by high performance liquid chromatography with tandem mass spectrometry in a case of severe intoxication. Drug Test Anal 6:764-9
Ignatowska-Jankowska, B M; Ghosh, S; Crowe, M S et al. (2014) In vivo characterization of the highly selective monoacylglycerol lipase inhibitor KML29: antinociceptive activity without cannabimimetic side effects. Br J Pharmacol 171:1392-407
Bagdas, Deniz; Muldoon, Pretal P; Zhu, Andy Z X et al. (2014) Effects of methoxsalen, a CYP2A5/6 inhibitor, on nicotine dependence behaviors in mice. Neuropharmacology 85:67-72
Wolf, Carl E; Goldstein, Ashley; Poklis, Justin L et al. (2014) Evaluation of an enzyme immunoassay for the detection of methadone metabolite EDDP [2-ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine] in urine. J Clin Lab Anal 28:136-40
Burston, James J; Sagar, Devi Rani; Shao, Pin et al. (2013) Cannabinoid CB2 receptors regulate central sensitization and pain responses associated with osteoarthritis of the knee joint. PLoS One 8:e80440

Showing the most recent 10 out of 106 publications